8-K: Ainos Secures $1.75 Million in Follow-On Funding, Amends Convertible Note

Ainos, Inc. has secured an additional $1.75 million in funding through an amendment to its existing convertible promissory note with Lind Global Fund II L.P., extending the maturity date and adjusting other terms.

Summary

• Ainos, Inc. has obtained $1.75 million in additional funding from Lind Global Fund II L.P. through an amendment to a senior secured convertible promissory note.
• The funding is split into two tranches: $875,000 was funded at closing, and the remaining $875,000 will be funded upon the effectiveness of a registration statement and other conditions.
• The maturity date of the note has been extended to March 28, 2025, with a further option to extend to July 28, 2025.
• If the maturity date is extended, the principal amount will increase by 1% per month of extension, up to a maximum of 4%.
• The total principal amount of the note is now $4,235,000.
• The note is convertible into Ainos' common stock at an initial conversion price of $7.50 per share, adjusted for any reverse stock split.
• Ainos issued a warrant to the investor to purchase 1,021,400 shares at an exercise price of $2.16 per share.
• The company also issued warrants to placement agents to purchase 4,666 shares at an exercise price of $8.25 per share and paid a cash fee of 7% of the gross proceeds.
• The funds will be used to advance the VELDONA IND preparation and AI Nose VOC platform development.

Sentiment

Score: 7

Explanation: The document is generally positive as it secures additional funding for the company's operations and key projects. However, the terms of the financing, including the potential for dilution and increased debt, temper the overall sentiment.

Positives

• The additional funding of $1.75 million provides Ainos with capital to advance its key projects.
• The extension of the maturity date to March 28, 2025, with a potential further extension to July 28, 2025, provides Ainos with more time to execute its plans.
• The funds will be used to advance the VELDONA IND preparation and AI Nose VOC platform development, which are key strategic initiatives for the company.

Negatives

• The principal amount of the note increases by 1% per month if the maturity date is extended, up to a maximum of 4%, which increases the company's debt burden.
• The company issued warrants to the investor and placement agents, which could dilute existing shareholders.
• The minimum market capitalization requirement applicable to the Note was reduced to USD 7,000,000.00, which could be a concern if the company's market cap falls below this level.

Risks

• The company's market capitalization falling below $7 million for ten consecutive days could trigger an event of default, although this is not effective until 90 days after January 23, 2024.
• The company's ability to successfully develop and commercialize its products is subject to various risks, including regulatory approvals and market competition.
• The company's dependence on revenues from the sale of COVID-19 test kits and its VELDONA Pet product line is a risk factor.
• The company has a limited cash and history of losses, which could impact its ability to continue operations.

Future Outlook

The company plans to use the proceeds to fund programs planned for the first half of 2024, including preparation work for IND applications for VELDONA human drug candidates and advancing co-development of a volatile organic compound (VOC) sensing platform. Additional tranches of funding may be provided by mutual agreement of the Investor and the Company.

Management Comments

• We plan to use the proceeds to fund programs planned for the first half of 2024, including preparation work for IND applications for VELDONA human drug candidates and advancing co-development of a volatile organic compound (VOC) sensing platform, powered by AI Nose technology, in collaboration with NISD and Inabata, said Chun-Hsien Tsai, Chairman and CEO.

Industry Context

This funding is part of a broader trend of biotech companies seeking capital to advance their research and development programs. The focus on point-of-care testing and AI-driven diagnostics aligns with current industry trends in healthcare technology.

Comparison to Industry Standards

• The use of convertible notes and warrants is a common financing method for small-cap biotech companies like Ainos.
• The conversion price of $7.50 per share is a premium to the current share price, which is typical in these types of financings.
• The warrant coverage of 75% of the funded amount is within the range of what is seen in similar transactions.
• Companies like Ainos often rely on private placements to fund their operations, as they may not have access to traditional bank financing.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• Employees may benefit from the increased funding, which could support job security and growth.
• Customers may benefit from the development of new products and services.
• Creditors may be impacted by the increased debt burden.

Next Steps

• The company will file a registration statement covering the additional shares of common stock issuable under the note and warrants.
• The company will use the funds to advance VELDONA IND preparation and AI Nose VOC platform development.
• The company may receive additional tranches of funding by mutual agreement with the investor.

Key Dates

Keywords

funding, convertible note, warrants, VELDONA, AI Nose, private placement, Lind Global Fund II, maturity date, registration statement, common stock